Impact of intravenous naltrexone on intravenous morphine-induced high, drug liking, and euphoric effects in experienced, nondependent male opioid users

Drugs in R and D

Volumn 11, Issue 3, 2011, Pages 259-275

  Webster, Lynn R ^a   Johnson, Franklin K ^b   Stauffer, Joseph ^b,c   Setnik, Beatrice ^b   Ciric, Sabrina ^d  

^a Lifetree Clinical Research   (United States)

^b Alpharma Pharmaceuticals LLC   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d CELERION   (United States)

Author keywords

Morphine; Naltrexone; Opioid abuse

Indexed keywords

MORPHINE; NALTREXONE;

ADULT; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG DOSAGE FORM COMPARISON; EUPHORIA; HUMAN; MALE; PRIORITY JOURNAL; PUPILLOMETRY; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SELF REPORT; UNSPECIFIED SIDE EFFECT; VISUAL ANALOG SCALE;

ANALGESICS, OPIOID; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; DRUG INTERACTIONS; EUPHORIA; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MORPHINE; NALTREXONE; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; PAIN; PAIN MEASUREMENT; SUBSTANCE-RELATED DISORDERS; YOUNG ADULT;

EID: 79960879545     PISSN: 11745886     EISSN: 11796901     Source Type: Journal    
DOI: 10.2165/11593390-000000000-00000     Document Type: Article

References (41)

1. Sloan P, Babul N. Extended-release opioids for the management of chronic non-malignant pain. Expert Opin Drug Deliv 2006; 3 (4): 489-97
2. Woolf CJ, Hashmi M. Use and abuse of opioid analgesics: potential methods to prevent and deter non-medical consumption of prescription opioids. Curr Opin Investig Drugs 2004; 5 (1): 61-6
3. National Institute on Drug Abuse (NIDA). Prescription medications, NIDA news [online]. Available from URL: http://www.nida.nih.gov/DrugPages/ prescription.html [Accessed 2009 Apr 21]
4. Substance Abuse and Mental Health Services Administration. Results from the 2008 National Survey on Drug Use and Health: national findings [online]. Office of Applied Studies, NSDUH Series H-36, HHS publication no. (SMA) 09-4434. Rockville (MD). Available from URL: http:// oas.samhsa.gov [Accessed 2009 Oct 2]
5. Substance Abuse and Mental Health Services Administration. Drug Abuse Warning Network, 2006: national estimates of drug-related emergency department visits [online]. Office of Applied Studies, DAWN Series D-30, DHHS publication no. (SMA) 08-4339. Rockville (MD). Available from URL: http://dawninfo.samhsa. gov [Accessed 2010 Aug 1]
6. Substance Abuse and Mental Health Services Administration. Treatment of episode data set (TEDS) highlights: 2006; national admissions to substance abuse treatment services [online]. Office of Applied Studies, DASIS Series: S-40, DHHS publication no. (SMA) 08-4313. Rockville (MD). Available from URL: http://oas.samhsa.gov [Accessed 2010 Aug 1]
7. Hall AJ, Logan JE, Toblin RL, et al. Patterns of abuse among unintentional pharmaceutical overdose fatalities. JAMA 2008; 300 (22): 2613-20
8. Johnston LD, O'Malley PM, Bachman JG, et al. Monitoring the future: national results on adolescent drug use; overview of key findings, 2008. Bethesda (MD): National Institute on Drug Abuse, US Department of Health and Human Services, 2009. NIH publication no. 09-7401
9. Wright IV C, Kramer ED, Zalman MA, et al. Risk identification, risk assessment, and risk management of abusable drug formulations. Drug Alcohol Depend 2006; 83 (Suppl. 1): S68-76
10. Kuehn BM. Opioid prescriptions soar: increase in legitimate use as well as abuse. JAMA 2007; 297 (3): 249-51
11. Katz N. Abuse-deterrent opioid formulations: are they a pipe dream? Curr Rheumatol Rep 2008; 10 (1): 11-8
12. Katz NP, Adams EH, Chilcoat H, et al. Challenges in the development of prescription opioid abuse-deterrent formulations. Clin J Pain 2007; 23 (8): 648-60
13. McColl S, Sellers EM. Research design strategies to evaluate the impact of formulations on abuse liability. Drug Alcohol Depend 2006; 83 (Suppl. 1): S52-62
14. House of Representatives. Making appropriations for Agriculture, Rural Development, Food and Drug Administration, and related agencies programs for the fiscal year ending September 30, 2006, and for other purposes: conference report (to accompany H.R. 2744), 109-255; 109th Congress, 1st Session, 2005
15. Center for Drug Evaluation and Research, FDA, US Department of Health and Human Services (statement of Sandra L Kweder, MD, Deputy Director, Office of New Drugs). Prevention of prescription drug abuse before the Subcommittee on Criminal Justice, Drug Policy and Human Resources House Committee on Government Reform (2006 Jul 26)
16. National Center for Injury Prevention and Control, Centers forDisease Control and Prevention,USDepartment ofHealth and Human Services (statement of Leonard J Paulozzi, MD, MPH, medical epidemiologist). Trends in unintentional drug overdose deaths before the Senate Judiciary Subcommittee on Crime and Drugs (2008 Mar 12)
17. Gonzalez JP, Brogden RN. Naltrexone: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence. Drugs 1988; 35 (3): 192-213
18. Naltrexone hydrochloride tablets [package insert]. Hazelwood (MO): Mallinckrodt Inc., 2009
19. Vivitrol [package insert]. Frazer (PA): Cephalon Inc., 2007
20. EMBEDA- [package insert]. Bristol (TN): King Pharmaceuticals Inc., June 2009
21. Stauffer J, Setnik B, Sokolowska M, et al. Subjective effects and safety of whole and tampered morphine sulfate and naltrexone hydrochloride (ALO-01) extended-release capsules versus morphine solution and placebo in experienced non-dependent opioid users: a randomized, double-blind, placebo-controlled, crossover study. Clin Drug Investig 2009; 29 (12): 777-90
22. Johnson FK, Stark JG, Bieberdorf FA, et al. Relative oral bioavailability of morphine and naltrexone derived from crushed morphine sulfate and naltrexone hydrochloride extended-release capsules versus intact product and versus naltrexone solution: a single-dose, randomized-sequence, open-label, three-way crossover trial in healthy volunteers. Clin Ther 2010; 32 (6): 1149-64
23. Cole JO, Orzack MH, Beake B, et al. Assessment of the abuse liability of buspirone in recreational sedative users. J Clin Psychiatry 1982; 43 (12 Pt 2): 69-75
24. Cicero TJ, Surratt H, Inciardi JA, et al. Relationship between therapeutic use and abuse of opioid analgesics in rural, suburban, and urban locations in the United States. Pharmacoepidemiol Drug Saf 2007; 16 (8): 827-40
25. International Conference on Harmonisation. ICH Topic E 6 (R1) guideline for good clinical practice [online]. European Medicines Agency. Available from URL: . emea.europa.eu/pdfs/human/ich/013595en.pdf [Accessed 2010 Aug 1]
26. World Medical Association (WMA). WMA Declaration of Helsinki: ethical principles for medical research involving human subjects [online]. Available from URL: http:// www.wma.net/en/30publications/10policies/b3/index.html [Accessed 2011 Jan 5]
27. Jasinski DR. Assessment of the abuse potentiality of morphinelike drugs (methods used in man). In: Martin W R, editor. Drug Addiction. New York (NY): Springer-Verlag, 1977: 197-258
28. Shram MJ, Sathyan G, Khanna S, et al. Evaluation of the abuse potential of extended release hydromorphone versus immediate release hydromorphone. J Clin Psychopharmacol 2010; 30 (1): 25-33
29. Knaggs RD, Crighton IM, Cobby TF, et al. The papillary effects of intravenous morphine, codeine, and tramadol in volunteers. Anesth Analg 2004; 99 (1): 108-12
30. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Royal Stat Soc Series B 1995; 57 (1): 289-300
31. Data on file. Natick (MA): Analgesic Solutions, 2011
32. Ghodse AH, Greaves JL, Lynch D. Evaluation of the opioid addiction test in an out-patient drug dependency unit. Br J Psychiatry 1999; 175: 158-62
33. Fliegert F, Kurth B, Gö hler K. The effects of tramadol on static and dynamic pupillometry in healthy subjects: the relationship between pharmacodynamics, pharmacokinetics and CYP2D6 metaboliser status. Eur J Clin Pharmacol 2005; 61 (4): 257-66
34. Stoops WW, Hatton KW, Lofwall MR, et al. Intravenous oxycodone, hydrocodone, and morphine in recreational opioid users: abuse potential and relative potencies. Psychopharmacology (Berl) 2010; 212 (2): 193-203
35. Balster RL, Bigelow GE. Guidelines and methodological reviews concerning drug abuse liability assessment. Drug Alcohol Depend 2003; 70 (3 Suppl.): S13-40
36. Azolosa JL, Stitzer ML, Greenwald MK. Opioid physical dependence development: effects of single versus repeated morphine pretreatments and of subjects' opioid exposure history. Psychopharmacology (Berl) 1994; 114 (1): 71-80
37. US Department of Health and Human Services, FDA. Guidance for industry: assessment of abuse potential of drugs. Rockville (MD): US Department of Health and Human Services, 2010 [online]. Available from URL: http://www.fda.gov/cder/ guidance/index.htm [Accessed 2011Jul 17]
38. National Advisory Council on Drug Abuse (NACDA). NACDA guidelines for administration of drugs to human subjects [online]. Available from URL: . gov/funding/hsguide.html [Accessed 2010 Aug 1]
39. Dershwitz M, Walsh JL, Morishige RJ, et al. Pharmacokinetics and pharmacodynamics of inhaled versus intravenous morphine in healthy volunteers. Anesthesiology 2000; 93 (3): 619-28
40. Kaufman MJ, Levin JM, Kukes TJ, et al. Illicit cocaine use patterns in intravenous-naive cocaine users following investigational intravenous cocaine administration. Drug Alcohol Depend 2000; 58 (1-2): 35-42
41. Chou R, Fanciullo GJ, Fine PG, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 2009; 10 (2): 113-30